RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

StatusUnknown
PhasePhase 1/2
Started

Record status This record was last updated January 8, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Recruiting
  2. Primary completion date: Sep 2023 to Sep 2025
    • Study completion date: Sep 2024 to Sep 2026
    • Start date changed from estimate of Sep 2022 to Sep 20, 2022
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jul 2022 to Sep 2022
    • Site details revised at 3 of 3 sites
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study was a single-arm, open, multi-center Phase Ib/II clinical trial to observe and evaluate the efficacy and safety of RC48-ADC plus S-1 in first-line treatment of advanced gastroesophageal adenocarcinoma with moderate expression of HER2.
Trial Details
NCT Number NCT05403242
Lead Sponsor Chinese PLA General Hospital
Conditions
(from sponsor)		 Advanced Gastroesophageal Adenocarcinoma
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov